Search alternatives:
mm decrease » a decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
mg decrease » a decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
c decrease » c decreased (Expand Search), a decrease (Expand Search), rc decreased (Expand Search)
_ decrease » _ decreased (Expand Search)
50 mm » 50 mg (Expand Search), 10 mm (Expand Search), 20 mm (Expand Search)
50 c » 5 c (Expand Search), 50 μ (Expand Search), 50 _ (Expand Search)
mm decrease » a decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
mg decrease » a decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
c decrease » c decreased (Expand Search), a decrease (Expand Search), rc decreased (Expand Search)
_ decrease » _ decreased (Expand Search)
50 mm » 50 mg (Expand Search), 10 mm (Expand Search), 20 mm (Expand Search)
50 c » 5 c (Expand Search), 50 μ (Expand Search), 50 _ (Expand Search)
-
1
FTY720 treatment decreased tumor growth in a xenograft model of hepatoblastoma.
Published 2019“…When tumors reached an average of 150 mm<sup>3</sup>, mice were randomized to receive vehicle (ORA-Plus, 50 μL, n = 7) or FTY720 (10 mg/kg body weight/day in ORA-Plus, 50 μL, n = 7) by oral gavage for 16 days. …”
-
2
-
3
-
4
-
5
-
6
mGluR5 receptor decreased glycinergic currents.
Published 2019“…(<b>E</b>) The inhibitory effect of CHPG on GlyR-IPSCs was not blocked by intracellularly loaded GDP-β-S (62.3 ± 6.4% of baseline at 15–20 min post-CHPG, <i>t</i>[6] = 2.782, <i>p</i> = 0.032), chelerythrine (60.9 ± 11.3% of baseline at 15–20 min post-CHPG, <i>t</i>[6] = 2.705, <i>p</i> = 0.035), or Ro-32-0432 (69.9 ± 3.2% of baseline at 15–20 min post-CHPG, <i>t</i>[5] = 8.495, <i>p</i> < 0.001). (<b>F</b>) Postsynaptic loading of U-0126 or PD98059 prevented CHPG from decreasing glycinergic responses (U-0126, 107.6 ± 10.4% of baseline at 15–20 min post-CHPG, <i>t</i>[8] = 0.997, <i>p</i> = 0.348; PD98059, 93.1 ± 5.0% of baseline at 15–20 min post-CHPG, <i>t</i>[5] = 0.883, <i>p</i> = 0.418). …”
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
Olaparib reverses the oxLDL-mediated decrease in co-immunoprecipitation of IκBα with RelA or p50.
Published 2024“…<p>Cell lysates were obtained from THP-1 monocytes exposed to reagents as indicated: Lane 1, vehicle; Lane 2, PARP inhibitor olaparib (5 mM, 24 hr); Lane 3, oxLDL (100 mg/mL, 24 hr) or Lane 4, combination of oxLDL and olaparib. …”
-
20